<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02698059</url>
  </required_header>
  <id_info>
    <org_study_id>iNAP®-CE-1501</org_study_id>
    <nct_id>NCT02698059</nct_id>
  </id_info>
  <brief_title>A Post-marketing Surveillance of the Negative Pressure Sleep Therapy System to Treat Obstructive Sleep Apnea</brief_title>
  <official_title>A Multi-center, Two-stage, Single-arm, Prospective, First-night Order Cross-over, Evaluator-blind Study to Evaluate the Efficacy, Safety and Tolerance of the iNAP® Sleep Therapy System in Adults With Obstructive Sleep Apnea (OSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Somnics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Somnics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a post-marketing surveillance study to investigate the efficacy and safety of the
      Negative Pressure Sleep Therapy System for the treatment of obstructive sleep apnea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, two-stage, single-arm, prospective, first-night order cross-over,
      evaluator-blind, post-marketing surveillance study to evaluate the efficacy, safety and
      tolerance of the iNAP® Sleep Therapy System (iNAP), a tongue and soft palate retaining
      intraoral device, in adults with obstructive sleep apnea (OSA).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical success rate* of apnea-hypopnea index (AHI)** on the 1st Tx PSG Night when compared to the Baseline PSG Night.</measure>
    <time_frame>first treatment night</time_frame>
    <description>*Clinical success rate is defined as the ratio of the number of patients with an AHI reduction of &gt;50% and treated AHI &lt;20 to the number of patients who complete the 1st Tx PSG Night, where completion is defined as a total sleep time (TST) and device negative pressure maintenance ≥4 hours/night on the 1st Tx PSG Night. For completion of the Baseline PSG Study, a total sleep time (TST) ≥4 hours/night has to be met.
**AHI is the number of apnea/hypopnea events divided by total sleep time (TST), i.e., the number of hours of sleep.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AE/SAE rate and type</measure>
    <time_frame>The whole study period through study completion; up to 8 weeks</time_frame>
    <description>Vital signs, Physical examination (PE) findings and change of body figure indexes, Electrocardiogram (ECG) findings as reflected in polysomnography (PSG), Adverse events (AEs), Serious adverse events (SAEs), Changes in the oral and dental condition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success rate* of apnea-hypopnea index (AHI)** on the 2nd Tx PSG Night when compared to the 1st Tx PSG Night.</measure>
    <time_frame>second treatment night</time_frame>
    <description>*Clinical success rate is defined as the ratio of the number of patients with an AHI reduction of &gt;50% and treated AHI &lt;20 to the number of patients who complete the 2nd Tx PSG Night, where completion is defined as a total sleep time (TST) and device negative pressure maintenance ≥4 hours/night on the 2nd Tx PSG Night. For completion of the Baseline PSG Study, a total sleep time (TST) ≥4 hours/night has to be met.
**AHI is the number of apnea/hypopnea events divided by total sleep time (TST), i.e., the number of hours of sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Oxygen Desaturation Index (ODI)* from the Baseline PSG Night compared to the 1st Tx PSG Night and the 2nd Tx PSG Night; and the change from the 1st Tx PSG Night compared to the 2nd Tx PSG Night.</measure>
    <time_frame>At the Baseline PSG Night, the 1st Tx PSG Night and/or the 2nd Tx PSG Night</time_frame>
    <description>*ODI is the event number of oxygen level drops by 3 percent or more from baseline divided by total sleep time (TST), i.e., the number of hours of sleep.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Obstructive Sleep Apnea (OSA)</condition>
  <arm_group>
    <arm_group_label>Treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iNAP® Sleep Therapy System Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baseline/Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Self-controlled, pre-treatment baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iNAP® Sleep Therapy System (iNAP)</intervention_name>
    <description>The iNAP provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.</description>
    <arm_group_label>Treated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) Female or male adults with age between 18~65 years old. (S1)

          -  2) Non-obese patients with body mass index (BMI) &lt;29 kg/m2. (S1)

          -  3) Patients able to read and sign on the informed consent form and able to comply with
             study requirements. (S1)

          -  4) Patients able to be properly fitted* with the oral interface as observed by the
             device feasibility test. (S1)

          -  5) Patients with oxygen desaturation index (ODI) between 10~40 (S2).

          -  6) Patients with oral negative vacuum time maintained* by iNAP® ≥4 hours/night and
             total sleep time (TST) ≥4 hours/night (S3).

               -  iNAP® pressure more negative than -30 mmHg will be considered evidence of
                  effective oral appliance application.

          -  7) Patients with apnea-hypopnea index (AHI) between 10~40 and TST ≥4 hours/night
             (Baseline PSG Night).

          -  8) Patients with oral negative vacuum time maintained* by iNAP® ≥4 hours/night and TST
             ≥4 hours/night (1st Tx PSG Night).

               -  iNAP® pressure more negative than -30 mmHg will be considered evidence of
                  effective oral appliance application.

        Exclusion Criteria:

          -  1) Patients who are allergic to silicone.

          -  2) Patients with obstructed nasal passages as evidenced by the inability to breathe
             through the nose with the mouth closed.

          -  3) Patients who recently experienced a near-miss or prior automobile accident due to
             sleepiness.

          -  4) Patients who have or have had hypoxemia (SpO2 &lt;80%) in the past six months caused
             by diseases other than OSA such as cardiac disease or severe pulmonary/respiratory
             disorders such as chronic obstructive pulmonary disease (COPD), interstitial lung
             disease, pneumothorax, pneumonia, etc.

          -  5) Female patients who are lactating, pregnant or intend to become pregnant during the
             study period.

          -  6) Patients with primary insomnia or any concomitant diagnosed or suspected sleep
             disorder.

          -  7) Patients with muscle disease, central nervous disease or chronic neurological
             disorders, including central sleep apnea*.

               -  Central sleep apnea is defined as a central apnea index (CAI) ≥ 5/hr or if
                  central sleep apnea accounts for ≥ 50% of the total AHI.

          -  8) Patients in whom it is not suitable to use iNAP® in the opinion of the Investigator
             including, but not limited to, alcohol or substance abuse, loose teeth, missing teeth,
             or grinding teeth, completed deviated septum (Type IV or VII) or completed closed
             nostrils or advanced periodontal disease or tonsillar volumes greater than grade 3.

          -  9) Patients with an inability to sleep through the night including, but not limited
             to, menopausal hot flashes, working at nights or rotating night shifts, planned travel
             across four or more time zones during the study period or within one week prior to
             study participation, or a sleep schedule not compatible with study site practices.

          -  10) Patients with potential complications of sleep apnea that, in the opinion of the
             Investigator, may affect the study interpretation or the health or safety of the
             patients including, but not limited to, narcolepsy, restless leg syndrome,
             nasopharyngeal carcinoma (NPC), end stage renal failure, a history of severe
             cardiovascular disease (including New York Heart Association (NYHA) class III or IV
             cardiac failure, coronary artery disease with angina or myocardial infarction/stroke
             in the past six months, uncontrolled hypertension or hypotension or cardiac
             arrhythmias), unstable heart or renal transplantation or use of medicine or other
             treatment(s) that may confound the result of the study or pose additional risks to the
             patient, such as oral anticoagulants or other agents making patients prone to tongue
             hemorrhage.

        Stage II Inclusion Criteria:

        Patients who fulfill all the enrollment criteria of Stage I and whose treated AHI on the
        1st Tx PSG Night is below 40.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hartmut Schneider, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Sleep Clinic Frankfurt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>C.C. Chen, Ph.D.</last_name>
    <email>chungchu1@somnics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>C.N. Huang, Ph.D.</last_name>
    <email>huangcn@somnics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>INTERSOM</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lennart Knaack</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Somnolab</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Christian Blum</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alfred Krupp Krankenhaus</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Stoohs</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>American Sleep Clinic</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hartmut Schneider</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinik Ambrock</name>
      <address>
        <city>Hagen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Nilius</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Bethanien</name>
      <address>
        <city>Solingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Randerath</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>104</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Shin Kong Wu Ho-Su Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>111</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chia-Mo Lin</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>February 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2016</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

